Files

Abstract

Cancer cachexia is a co-morbidity highly prevalent in pancreatic ductal adenocarcinoma (PDAC) patients and results in a decreased quality of life.This work expands on prior knowledge of IL-6 in cancer cachexia, implicates impaired hepatic metabolism as an early event in cachexia progression, and highlights the liver as a target for potential interventions in cachexia treatment.

Details

PDF

Statistics

from
to
Export
Download Full History